Yamanaka Hisashi
Institute of Rheumatology, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan.
Endocr Metab Immune Disord Drug Targets. 2015;15(2):129-34. doi: 10.2174/1871530315666150316121808.
Anti-Tumor Necrosis Factor (TNF) agents were the first molecular targeting drugs developed for the treatment of rheumatoid arthritis (RA). Anti-TNF agents improve the clinical picture of severe RA patients, inhibit joint destruction and improve quality of life. In the 15 years since their introduction, they have become the preferred drug therapy for management of RA. The success of anti-TNF agents in the treatment of RA has resulted in the development of many drugs for other inflammatory diseases using the same molecular targeting concept. However, many unresolved issues surround the use of anti-TNF agents, including the risk for infection, primary non-responders, secondary loss of efficacy and pharmacoeconomical issues. This review focuses on the multifaceted impact of anti-TNF agents in the treatment of RA.
抗肿瘤坏死因子（TNF）药物是首批研发用于治疗类风湿关节炎（RA）的分子靶向药物。抗TNF药物可改善重症RA患者的临床表现，抑制关节破坏并提高生活质量。自引入以来的15年里，它们已成为RA治疗的首选药物疗法。抗TNF药物在RA治疗中的成功促使许多采用相同分子靶向概念的药物被开发用于其他炎症性疾病。然而，围绕抗TNF药物的使用仍存在许多未解决的问题，包括感染风险、原发性无应答者、继发性疗效丧失以及药物经济学问题。本综述聚焦于抗TNF药物在RA治疗中的多方面影响。
